Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

COMPLETED RESEARCH: CLINICAL/TRANSLATIONAL RESEARCH
Abstract #CT05

Cost of Cancer Management by Stage of Diagnosis Among Medicare Beneficiaries

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Cost of Care

Presenter: Karen C. Chung, PharmD, MS, Senior Director, Health Economics & Outcomes Research, GRAIL

Co-Authors: Eunice Chang, GRAIL; Anuraag R. Kansal, GRAIL; Sheila R. Reddy, GRAIL

Background: A diagnosis of cancer at earlier stages may offer patients less extensive and less costly treatment with decreased morbidity and mortality. The advent of blood-based circulating tumor cell–free DNA simultaneously to detect and to localize multiple cancer types may enable early cancer detection and the potential to improve patient outcomes and reduce the burden of cancer.

Objective: To estimate the cancer-related cost of care after a cancer diagnosis among Medicare beneficiaries, by disease stage at diagnosis.

Methods: We used 2012-2016 data from the linked Surveillance, Epidemiology, and End Results (SEER) registry-Medicare claims database to examine cost of care among Medicare patients with a confirmed cancer—including hormone receptor (HR)-positive, HR-negative breast cancer, colon, esophagus, head and neck, kidney, liver, lung, lymphoid, ovarian, pancreatic, prostate, or stomach cancer—based on the International Classification of Diseases for Oncology, Third edition, histology codes reported in SEER. Patients contributed to the calculation of annual costs (years 1-5) using their observed time after diagnosis; thus, each annualized calculation consisted of a different sample. Patients were continuously enrolled in fee-for-service Medicare Part A or Part B and Part D during follow-up. Total, inpatient, outpatient, and pharmacy cancer-related service costs were calculated.

Results: From 2012 to 2016, we identified 613,639 Medicare beneficiaries with incident cancer diagnosis within 5 years (stage I, II, III, and IV: 26.9%, 31.2%, 14.4%, and 16.8%, respectively; 10.6% of patients lacked stage information). Across all 13 cancer cohorts (N = 6775-135,663), mean (standard deviation [SD]) age ranged from 68.0 (11.0) to 74.2 (10.0) years. In year 1, mean (SD) total costs for stage I diagnoses varied from $33,033 ($46,609) for prostate, to $129,254 ($142,600) for pancreatic cancer. Total costs increased by disease stage and reached $76,314 ($108,425) for prostate to $196,302 ($205,370) for liver cancer for stage IV diagnoses in year 1; stage IV total costs were 1.4 for pancreatic to 2.7 for HR-positive breast or kidney cancer times the stage I costs. Inpatient costs were the largest share of year 1 total costs for the majority of cancers, ranging from $5558 ($23,739) for HR-positive breast to $78,148 ($119,143) for pancreatic cancer for stage I diagnoses, and $37,399 ($90,065) for prostate to $123,416 ($183,116) for liver cancer for stage IV diagnoses. In years 2 to 5, the total costs were notably lower than in year 1, but continued to increase by disease stage.

Conclusions: Patients diagnosed at later stages of cancer have considerably higher costs of care than those diagnosed at earlier stages. Earlier cancer diagnosis may lead to more efficient treatment and decreased management cost.

Related Items
Welcome to the First Annual Issue of HOPA Abstracts, 2021
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts
Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Patients with Multiple Myeloma Receiving Lenalidomide, Bortezomib, and Dexamethasone
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Multiple Myeloma
Correlation of BRAF Mutation Status in Circulating Tumor DNA with Tumor Biopsy and Clinical Outcomes in the COLUMBUS Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Targeted Therapies
Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600E–Positive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Colorectal Cancer
Incidence of Adverse Effects in Patients with Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Lymphoid Blast Crisis Receiving Ponatinib with or without Concomitant Azole Antifungals
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Leukemia
In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Updated Real-World Results from the Community-Based US MM-6 Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Real-World Dosing Patterns of Ruxolitinib Among Patients with Myelofibrosis: A US Community Oncology Practice
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Oncology Pharmacy Programs, Myelofibrosis
Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Leukemia, Lymphoma
Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Gynecologic Cancers
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.